ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2016
Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- Establishment of a chinchilla model ofMicrobiology spectrum · 2026Article
- Analysis of virulence of the emerging opportunistic human pathogen Achromobacter in a zebrafish embryo model.BMC microbiology · 2026Article
- Differential Evolution ofPathogens (Basel, Switzerland) · 2026Article
- The cystic fibrosis pathogenJournal of medical microbiology · 2025Article
- Antibody-guided identification ofmSphere · 2025Article
- The Association ofJournal of clinical medicine · 2025Article
- Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung.PLoS pathogens · 2025Article
- Development of a Simple and Accurate Molecular Protocol Using 16SrRNA for Species-Specific Identification ofPathogens (Basel, Switzerland) · 2025Article
- Genetic and Biochemical Characterization of AXC-2 fromPathogens (Basel, Switzerland) · 2024Article
- Exoproducts of the Most CommonMicrobiology spectrum · 2023Article
- In Vivo Inflammation Caused byInternational journal of molecular sciences · 2023Article
- Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future.Antibiotics (Basel, Switzerland) · 2023Review
- Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?Frontiers in medicine · 2023Review
- The Efficacy of an N-Acetylcysteine-Antibiotic Combination Therapy onBiomedicines · 2022Article
- Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis.Children (Basel, Switzerland) · 2022Article
- TheMicrobiology spectrum · 2022Article
- Article
- Characterization of theFrontiers in cellular and infection microbiology · 2022Article
- Adaptive Interactions ofPathogens (Basel, Switzerland) · 2021Article
- Role of RND Efflux Pumps in Drug Resistance of Cystic Fibrosis Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rate of diagnosis of colonization/infection of the airways with Achromobacter xylosoxidans has increased in cystic fibrosis patients, but its clinical significance is still controversial. This retrospective, case-control study aimed to evaluate the clinical impact of A. xylosoxidans colonization/infection in cystic fibrosis patients. Individuals who were chronically colonized/infected (n=10), intermittently colonized/infected (n=15), and never colonized/infected with A. xylosoxidans (n=18) were retrospectively evaluated during two periods that were 2 years apart. Demographic characteristics, clinical data, lung function, and chronic bacterial co-colonization data were evaluated. Of the total study population, 87% were pediatric patients and 65.1% were female. Individuals chronically colonized/infected with A. xylosoxidans had decreased forced expiratory volume in 1 s (51.7% in the chronic colonization/infection group vs 82.7% in the intermittent colonization/infection group vs 76% in the never colonized/infected group). Compared with the other two groups, the rate of co-colonization with methicillin-resistant Staphylococcus aureus was higher in individuals chronically colonized/infected with A. xylosoxidans (P=0.002). Changes in lung function over 2 years in the three groups were not significant, although a trend toward a greater decrease in lung function was observed in the chronically colonized/infected group. Compared with the other two groups, there was a greater number of annual hospitalizations in patients chronically colonized/infected with A. xylosoxidans (P=0.033). In cystic fibrosis patients, there was an increased frequency of A. xylosoxidans colonization/infection in children, and lung function was reduced in patients who were chronically colonized/infected with A. xylosoxidans. Additionally, there were no differences in clinical outcomes during the 2-year period, except for an increased number of hospitalizations in patients with A. xylosoxidans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.